Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from hypericum
Reexamination Certificate
1998-06-17
2001-06-12
Witz, Jean C. (Department: 1651)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from hypericum
Reexamination Certificate
active
06245362
ABSTRACT:
The invention relates to a medication for treatment of a disease caused by a virus, particularly a retrovirus, based on the active agents of the plant Hypericum (St. John's Wort) and to a method of production of the medication.
BACKGROUND OF THE INVENTION
The plant St. John's Wort as well as its applicability as a pharmaceutical were already known to people of antiquity. Most of the approximately 370 species of this plant worldwide comprise the red pigment hypericin, a naphthodianthrone derivative having a molecular weight of 504.43 and the empirical formula C
30
H
16
O
8
. In addition to hypericin, a number of structural analogs was identified which have been described in the literature as pseudohypericin, protohypericin, protopseudohypericin, cyclopseudohypericin, isohypericin, Kielcortin etc., so-called polycyclic diones. Other components of the plant are, for example, the flavonoid quertecine as well as other bioflavonoids and flavonoid glycosides, vegetable acids such as chlorogenic and coffeic acid, hyperforin—a phloroglucine derivative—tanning agents, flower pigments as well as cyanidin chloride and xantophyll, anthraquinone, xanthone derivatives, distilled oils such as terpineol, resin-like substances, fats and waxes.
It has recently been found that polycyclic diones (hypericin, pseudohypericin and/or salts thereof) in highly pure form have antiviral efficacy. In particular, an inhibiting effect on retrovirus can be observed in vitro (cf. EP 0 332 697 B1); this applies also with respect to the human immunodeficiency virus (HIV) which in humans causes the acquired immune deficiency syndrome (AIDS). Hypericin or pseudohypericin were herein used in highly pure form. In order to obtain this form, the extract from the plant Hypericum was treated until nearly pure hypericin/pseudohypericin was obtained. Alternatively, highly pure hypericin was produced synthetically. The medications suggested in this connection comprised nearly pure hypericin/pseudohypericin (or pharmaceutically efficacious salts thereof) as the sole active agent, and, in addition, pharmacologically known solvents and carrier substances suitable in known manner for various forms of administration and dosages.
It has also been suggested to combine for the treatment of diseases caused by retrovirus the administration of hypericin/pseudohypericin with the administration of nucleoside analogs WO 89/09056. However, herein also nearly pure hypericin/pseudohypericin was used.
However, animal experiments have shown that when using highly pure hypericin/pseudohypericin, strong side effects in the form of hyperphotosensitization can occur. Due to this effect, the therapeutic application of preparations with highly pure hypericin/pseudohypericin must be ruled out. Therefore, this approach has not been pursued further and no Hypericum preparations for antiviral application have been introduced on the market.
In addition, in the field of medicine, Hypericum preparations have long been used based on extracts of the plant for various indications in the psychogenic area such as depressions in the absence of endogenous forms, sleep disorders and psychogenically caused other disorders such as bed wetting. An oily preparation from the plant (oleum hypericin) for external application in the treatment of wounds and pain is additionally known. The internal application of oleum hypericin has been recommended in the case of dyspeptic complaints.
The currently valid monograph by the Kommission E of the Bundesamt für Arzneimittel und Medizinprodukte (Federal Board for Pharmaceutical Drugs and Medical Products) lists as fields of application psychovegetative disorders, depressive states, anxiety and/or nervous agitation. All currently known Hypericum-containing pharmaceutical drugs concern this range of indications of psychogenic disorders and sleep disorders.
The known Hypericum-containing pharmaceutical drugs are based on the extract from the plant with a content of polycyclic diones (hypericin, pseudohypericin and/or salts thereof) of less than 1%. The listed active agents are thus not present in a pure state. The use of such preparations for the indications in viral illnesses is not known.
This range of indications had previously only been suggested for highly pure hypericin/pseudohypericin preparations but which, due to the above cited side effects, cannot be used therapeutically.
SUMMARY OF THE INVENTION
It is therefore the task of the invention to make therapeutically usable the antiviral, in particular antiretroviral, effect of polycyclic diones (hypericin, pseudohypericin and/or salts thereof) while largely avoiding the described side effects.
The invention rests on the surprising finding that the inhibition of retrovirus known for highly pure hypericin/pseudohypericin can also be attained with hypericin/pseudohypericin in lower concentrations provided sufficient dosages of hypericin/pseudohypericin are being administered. For this purpose, the active agents (hypericin, pseudohypericin and/or salts thereof) are mixed with other substances known to be components of the plant Hypericum or extracts are used which comprise the active agent (hypericin, pseudohypericin and/or salts thereof) in similarly low or slightly more concentrated form than in the preparations known for the treatment of psychogenic disorders and sleep disorders, thus in concentrations from between 0.05% and 50% of polycyclic diones, however these extracts do not {comprise the active agent} in highly pure form.
Surprisingly, herein the side effects known in connection with highly pure hypericin/pseudohypericin do not occur and specifically also in dosages which exceed by a multiple the dosages which had previously been used for Hypericum extract preparations for other indications (psychogenic disorders, sleep disorders). The extract obtained from the plant, with concentrations of polycyclic diones between 0.05% and 50% while retaining other substances comprised in the plant in concentration between 50% and 99.95% can consequently be used therapeutically for the treatment of viral diseases.
REFERENCES:
patent: 4898891 (1990-02-01), Lavie et al.
patent: 5047435 (1991-09-01), Lavie et al.
patent: 5049589 (1991-09-01), Lavie et al.
patent: 5120412 (1992-06-01), Mazur et al.
patent: 5288485 (1994-02-01), Kikuta et al.
patent: 5514714 (1996-05-01), Meruelo et al.
patent: 5820867 (1998-10-01), Bewicke
patent: 3935772 (1991-04-01), None
patent: 79428 (1983-02-01), None
Ozturk, Y. et al., Phytotherapy Research, vol. 6(1), p. 44-46, 1992.*
Meruelo, D. et al., Proc. Natl. Acad. Sci. USA, vol. 85(14), p. 5230-5234, Jul. 1988.
Elten Holger
Steinbeck-Klose Annemarie
Dreluso Pharmazeutika Dr. Elten & Sohn GmbH
Flanagan John K.
Flanagan John R.
Flanagan & Flanagan
Witz Jean C.
LandOfFree
Medication for treatment of viral disease based on active... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medication for treatment of viral disease based on active..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medication for treatment of viral disease based on active... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2542164